CME Presentations

SITC Pan Tumor


Presentations


Speakers

  • Roy Herbst, MD, PhD

    Roy Herbst, MD, PhD

    Roy Herbst, MD, PhD

    Ensign Professor of Medicine (Oncology)

    Roy S. Herbst, MD, PhD, is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut. Dr Herbst has led phase I development of several new-generation targeted agents for non-small cell lung cancer (NSCLC). His laboratory work, which focuses on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways, has been translated from preclinical to clinical settings in multiple Phase II and III studies. He has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters.
  • Joel W. Neal, MD, PhD

    Joel W. Neal, MD, PhD

    Joel W. Neal, MD, PhD

    Associate Professor of Medicine

  • Yelana Janjigian, MD

    Yelana Janjigian, MD

    Yelana Janjigian, MD

    Chief, Gastrointestinal Oncology Service

  • Michael J. Overman, MD

    Michael J. Overman, MD

    Michael J. Overman, MD

    Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine

    Michael J. Overman, MD, is a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston. Dr Overman is focused on improving the outcomes for patients with pancreatic and intestinal cancers, with a strong interest in clinical trials and translational research. He is a principal investigator on numerous studies investigating immune-checkpoint therapy in gastrointestinal malignancies, and has been involved in various clinical trial studies involving small bowel adenocarcinomas. He has published articles in peer-reviewed journals that include the Journal of Clinical Oncology and Annals of Oncology. Dr Overman earned his MD from Johns Hopkins School of Medicine in Baltimore, Maryland.

CME Information

PIM LogoPQH Logo

Immunotherapy Updates in GEJ and CRC

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with The Society for Immunotherapy of Cancer.

ACKNOWLEDGEMENT

Supported by educational grants from Genentech, Merck & Co., Inc, and Regeneron.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM Logo

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, MOC credit is reported on a monthly basis.

To claim and receive MOC credits, learners must provide:
  • ABIM ID number
  • First and last name
  • Degree and specialty
  • DOB (MMDD)
  • Activity completion date

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Pharmacist Continuing Education

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.1) CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-028-L04-P)
Type of Activity: Application

ENDURING CREDIT DESIGNATION STATEMENT

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Pharmacist Continuing Education

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.1) CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-029-H04-P)
Type of Activity: Application

DATE OF RELEASE/EXPIRATION

Live Activity

Tuesday, January 25, 2022, at 4:00 – 5:00 pm EST

Enduring Material

January 25, 2022 – January 25, 2023

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Discuss changes to the treatment algorithm and the issuance of updated guideline directed strategies to better incorporate immunotherapies into clinical practice
  • Evaluate the latest safety and efficacy data across checkpoint inhibitors for cancer treatment
  • Review new indications that expand the selection of treatment options
  • Integrate mitigation and management strategies for adverse events related to immunotherapies

TARGET AUDIENCE

The intended audience for this activity program are medical, surgical, and radiation oncologists, gastroenterologists, dermatologists, pulmonologists, primary care physicians, internal medicine specialists, oncology pharmacists, oncology advanced practice nurses and physician assistants, social workers and other HCPs who participate in the care of patients receiving immunotherapies.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com.To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1.0 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Yelena Y. Janjigian, MD
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Consultant/Independent Contractor: AstraZeneca, Basilea Pharmaceutica, Bristol-Myers Squibb, Merck Serono, RGENIX, Eli Lilly, Daiichi Sankyo, Pfizer, Bayer, Imugene, Merck, Zymeworks Inc., Seagen, Michael J. Hennessy Associates, Paradigm Medical Communications
Grant/Research Support: NCI, Department of Defense, Cycle For Survival, Fred’s team, RGENIX, Bayer, Genentech/Roche, Bristol Myers Squibb, Eli Lilly , Merck
Michael J. Overman, MD
Professor of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Consulting: Roche, BMS, Medimmune, Merck, Amgen, Takeda, Janssen, Pfizer, Array, Gritistone, 3DMed, Phanes
Research Funding: Takeda, Roche, Lilly, Merck, Medimmune, BMS, Apexigen, Gritstone

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive.com.com or ClinicalSeriesLive.com at 1-877-394-1306 or at Support@OMedLive.com.
PIM LogoPQH Logo

Checkpoint Inhibitor Updates and Emerging Approaches in Lung Cancer (SCLC and NSCLC)

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with The Society for Immunotherapy of Cancer.

ACKNOWLEDGEMENT

Supported by educational grants from Genetech, Merck & Co., Inc, and Regeneron.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM Logo

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, MOC credit is reported on a monthly basis.

To claim and receive MOC credits, learners must provide:
  • ABIM ID number
  • First and last name
  • Degree and specialty
  • DOB (MMDD)
  • Activity completion date

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Pharmacist Continuing Education

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15) CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-020-L04-P)
Type of Activity: Application

ENDURING CREDIT DESIGNATION STATEMENT

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Pharmacist Continuing Education

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15) CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-021-H04-P)
Type of Activity: Application

DATE OF RELEASE/EXPIRATION

Live Activity

Wednesday, January 12, 2022 at 4:00 – 5:30 pm EST

Enduring Material

January 12, 2022 – January 12, 2023

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Discuss changes to the treatment algorithm and the issuance of updated guideline directed strategies to better incorporate immunotherapies into clinical practice
  • Evaluate the latest safety and efficacy data across checkpoint inhibitors for cancer treatment
  • Review new indications that expand the selection of treatment options
  • Integrate mitigation and management strategies for adverse events related to immunotherapies

TARGET AUDIENCE

The intended audience for this activity program are medical, surgical, and radiation oncologists, gastroenterologists, dermatologists, pulmonologists, primary care physicians, internal medicine specialists, oncology pharmacists, oncology advanced practice nurses and physician assistants, social workers and other HCPs who participate in the care of patients receiving immunotherapies.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour and 30 minutes to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com.To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1.5 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
Consulting: Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Loxo Oncology, Merck and Company, Midas Health Analytics, Mirati Therapeutics, Nektar, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen
Research Support: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company Scientific Advisory Boards: Neon Therapeutics, Infinity Pharmaceuticals, NextCure
Advisory Board: Junshi Pharmaceuticals
Joel W. Neal, MD, PhD
Associate Professor of
Medicine, Division of Oncology
Medical Director for the Cancer Clinical
Trials Office (Stanford Cancer Institute)
Medical Director of Informatics
(Stanford Cancer Center)
Stanford, CA
Consulting: AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda Pharmaceuticals, Eli Lilly and Company, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, Natera, Sanofi/Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics
Research Funding: Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK, Janssen, AbbVie

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive.com.com or ClinicalSeriesLive.com at 1-877-394-1306 or at Support@OMedLive.com.